Cullinan Oncology Inc. (CGEM): Price and Financial Metrics
CGEM Price/Volume Stats
Current price | $12.58 | 52-week high | $30.19 |
Prev. close | $13.10 | 52-week low | $7.64 |
Day low | $12.50 | Volume | 854,700 |
Day high | $13.52 | Avg. volume | 654,171 |
50-day MA | $16.24 | Dividend yield | N/A |
200-day MA | $18.44 | Market Cap | 732.51M |
CGEM Stock Price Chart Interactive Chart >
Cullinan Oncology Inc. (CGEM) Company Bio
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Price Returns
1-mo | -21.13% |
3-mo | -30.23% |
6-mo | -47.87% |
1-year | 48.35% |
3-year | -32.04% |
5-year | N/A |
YTD | 23.45% |
2023 | -3.41% |
2022 | -31.63% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...